New acquisition of CF pathogens: PA · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for additional antibiotic therapy · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted · children with cystic fibrosis
1 finding from 1 review
Pulmonary exacerbations · children with cystic fibrosis
1 finding from 1 review
Organ system failure ‐ Renal insufficiency leading to replacement therapy · children with haematological malignancy at risk of tumour lysis syndrome
1 finding from 1 review
Serum urate normalisation ‐ not reported · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: high‐dose urate oxidase showed no clear difference in normalisation of serum uric acid ( compared with low‐dose urate oxidase (low certainty).
1 finding from 1 review
Percentage reduction in serum uric acid level · children with haematological malignancy at risk of tumour lysis syndrome
1 finding from 1 review
AUC of serum uric acid level · children with haematological malignancy at risk of tumour lysis syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: high‐dose urate oxidase showed no clear difference in frequency of adverse events ( compared with low‐dose urate oxidase (low certainty).
1 finding from 1 review
Incidence of clinical tumour lysis syndrome · children with haematological malignancy at risk of tumour lysis syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality due to tumour lysis syndrome · children with haematological malignancy at risk of tumour lysis syndrome
1 finding from 1 review
Time taken from start of treatment until the resolution of DIOS · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment failure rate · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adherence · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Episodes of acute DIOS · adults and children with cystic fibrosis
1 finding from 1 review
Adverse effects: abdominal mass · adults and children with cystic fibrosis
1 finding from 1 review
Abdominal pain · adults and children with cystic fibrosis
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review